NEW YORK (GenomeWeb News) – Celera today said that it has licensed exclusive worldwide rights to Bayer Schering Pharma for five cancer-related drug targets and associated in vivo diagnostic imaging.

The Alameda, Calif.-based molecular diagnostics firm said that it will retain in vitro diagnostic rights and will be able to develop and sell companion diagnostics specific to therapeutic compounds developed by Bayer under the deal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.